Bayer submits low-dose MRI contrast agent gadoquatrane for Japan approval
Bayer has submitted a groundbreaking marketing authorisation application to Japan’s Ministry of Health, Labour, and Welfare for gadoquatrane, an investigational contrast agent that could significantly improve MRI safety protocols. The macrocyclic agent delivers a remarkable 60% reduction in gadolinium exposure compared to standard-of-care agents, addressing critical concerns about cumulative gadolinium retention in patients requiring multiple […]